Glow Stack
Product Overview
“Glow Stack” is a commonly used name for the combined use of BPC-157 Acetate, TB-500 Acetate, and GHK-Cu. These three peptides have been studied primarily in animal and laboratory models for their possible roles in tissue repair, inflammation, and skin support.[1-5]
Empower Pharmacy does not compound these three ingredients together as a single product. Instead, a prescriber may choose to prescribe [BPC-157 Acetate Injection], [TB-500 Acetate Injection], and [GHK-Cu Capsules] as three separate medications to be used together.
Most of what is known about BPC-157, TB-500, and GHK-Cu comes from animal and laboratory studies. Very limited human data exists for BPC-157 and TB-500, and most human research on GHK-Cu comes from topical rather than oral use. 1-5 How well GHK-Cu is absorbed when taken by mouth is not yet well understood. [4,5]
None of these peptides is approved by the U.S. Food and Drug Administration for any use. The safety and efficacy of using these products together have not been established.
Use should be guided by a licensed healthcare provider with consideration of the limited clinical evidence available.
The information below reflects a commonly used dosing approach for each individual product. It is provided for general information only and is not a dosing recommendation. A prescribing provider may select a different amount, frequency, or duration based on the patient’s treatment goals, response, tolerability, medical history, concomitant therapies, and other patient-specific factors.
- BPC-157 Acetate Injection: Inject 250-500 mcg intramuscularly or subcutaneously once daily.
- TB-500 Acetate Injection: Inject 2.5 mg subcutaneously one to two times weekly for 4 to 6 weeks.
- GHK-Cu 2 mg Capsules: Take 1 capsule by mouth once daily.
Your prescribed amount, strength, frequency, or duration may differ from the common dosing information shown above. Use this medication only as directed on your prescription label, and do not change how you use it unless instructed by your prescribing provider. Contact your provider or pharmacist if you have questions about your individualized directions.
The proposed rationale for using BPC-157 Acetate, TB-500 Acetate, and GHK-Cu is described below. These mechanisms are primarily supported by preclinical studies, and the clinical relevance of these findings in humans remains under investigation. [1-5]
BPC-157 has been proposed to promote angiogenesis, support extracellular matrix remodeling, and modulate integrin signaling. [1,3]
TB-500 has been proposed to promote angiogenesis, support tissue repair through fibroblast activation and extracellular matrix remodeling, and regulate inflammatory responses through NF-κB pathway regulation. [1,2]
GHK-Cu has been proposed to stimulate collagen and extracellular matrix production, modulate expression of genes involved in tissue repair, inflammation, and antioxidant defense, modulate inflammatory cytokines and reduce oxidative stress, and support angiogenesis and wound healing responses. [4,5]
The GHK-Cu mechanisms have been primarily characterized in laboratory and dermatologic studies, and the clinical implications of oral administration have not been established in human trials. [4,5]
No studies have evaluated whether using the three peptides together provides any additional benefit compared with any one of them alone.
Due to limited human data, these products should be used with caution. Additional product-specific information is available on each individual product page.
- Safety and efficacy of the combined use have not been established
- Long-term safety data are not available
- Avoid use in patients with active malignancy, due to proposed effects on angiogenesis, growth signaling, and cellular remodeling
- For BPC-157 and TB-500, may pose risk for immunogenicity for certain routes of administration and may have complexities regarding peptide-related impurities [6]
- BPC-157 and TB-500 are each listed as prohibited substances by the World Anti-Doping Agency; athletes subject to anti-doping testing should be counseled accordingly [7]
- Limited clinical data are available for oral use of GHK-Cu
- Use caution with GHK-Cu capsules in patients with Wilson disease, impaired bile excretion, or those taking additional copper-containing supplements [8]
Therapy should be individualized and supervised by a qualified healthcare provider.
Formal drug interaction studies have not been conducted for any of the products, or for their use together. Given their proposed effects on angiogenesis, extracellular matrix remodeling, and inflammatory signaling, and the copper content of GHK-Cu Acetate, theoretical interactions may occur with:
- Anti-inflammatory or antioxidant agents
- Agents affecting angiogenesis, tissue growth, wound healing, or cell proliferation
- Agents affecting copper metabolism [8]
Patients should disclose all medications and supplements prior to use.
Clinical safety data in humans are limited for all three products, and the safety profile of their combined use has not been established. Based on available data and mechanism of action, potential side effects may include:
- Injection site reactions
- Flushing
- Hypersensitivity reactions
- Headache
- Vertigo
- Gastrointestinal upset
- Excess copper exposure
Refer to the individual product pages for component-specific information.
Any suspected side effects, medication errors, and concerns about this medication, such as the wrong strength, possible contamination, or problems with labeling or packaging, should be reported to the prescribing healthcare provider, Empower Pharmacy, and the FDA through MedWatch. For this compounded medication, reports should also be submitted to the appropriate state regulatory authority where the product was compounded and the state where it was shipped, if different.
There are no adequate and well-controlled studies evaluating BPC-157 Acetate, TB-500 Acetate, or GHK-Cu in pregnant or breastfeeding individuals. Due to the lack of safety data and potential effects on cellular growth, angiogenesis, and tissue remodeling, use during pregnancy and breastfeeding is contraindicated.
Dosing, administration, and storage instructions are specific to each product and differ between the injectable products and the oral capsules. Please refer to the [BPC-157 Acetate Injection], [TB-500 Acetate Injection], and [GHK-Cu Capsules] product pages and to your prescription label. Use each medication only as directed by your prescribing provider, and do not use any product beyond the beyond-use date provided by Empower.
Disclaimer
Compounded products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. Compounded products from our 503A facility are available only through a valid patient-specific prescription from a licensed prescriber and are prepared by a licensed pharmacy; shipping and state restrictions may apply. Compounded drug products from our 503B facility are only available for order by licensed healthcare providers and pharmacies. This document is for educational and informational use by healthcare professionals. It is not medical, legal, or regulatory advice, and it is not a promotion of any product. Except for products identified as currently available, it is not a statement of product availability.
Regulatory status
HHS’s interim policy is an expression of enforcement intent under stated conditions; it does not approve any product, change the requirements of the FD&C Act, or place any substance on the 503A Bulks List, which requires FDA rulemaking. PCAC recommendations are advisory. No dose of this product has been established as safe or effective in humans. State boards of pharmacy and medicine independently regulate compounding and prescribing. Regulatory status can change; confirm current status with FDA, HHS, and applicable state authorities before relying on this summary.
Reporting
Healthcare professionals and patients are encouraged to report suspected adverse events and product quality concerns to FDA MedWatch (fda.gov/medwatch; 1-800-FDA-1088).
- Rahman OF, Lee SJ, Seeds WA. Therapeutic peptides in orthopaedics: applications, challenges, and future directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1):e25.00236. Published 2026 Jan 2. doi:10.5435/JAAOSGlobal-D-25-00236
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi:10.1016/j.jchromb.2024.124033
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. Published online July 31, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA. Updated April 22, 2026. Accessed November 5, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. Effective January 1, 2026. Accessed November 6, 2026. https://www.wada-ama.org/en/prohibited-list
- US Food and Drug Administration. Copper (cupric chloride) [package insert]. DailyMed. Updated May 18, 2026. Accessed November 6, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc
What Is the HHS Peptide Enforcement Discretion Policy?
HHS’s peptide enforcement discretion policy is a statement that it does not intend to take enforcement action against certain peptide compounding when specific conditions are met. It is a draft interim policy that is not binding on HHS or the public, and it does not change Section 503A. The policy stays in place while FDA builds the 503A bulk drug substances list through rulemaking. It applies to state-licensed pharmacies, Federal facilities, and licensed physicians. A “licensed physician” here means one who compounds, not prescribers in general.
For prescribers, this changes the federal enforcement picture for the pharmacies you can work with, but it does not impact any state-specific laws or regulations that may exist in your state.
Which Peptides Does the Policy Cover?
Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Each is limited to the specific form and routes listed. A peptide not on the list, or in a different form or route, is outside the policy.
Source: Appendix B of the HHS policy. Appendix B defines each peptide by exact sequence and formula. For instance, it describes TB-500 as a fragment of its parent protein, thymosin beta-4. The full text is in the Federal Register notice.
Do Prescribers Need a Patient-Specific Prescription?
Yes. The policy names section 503A’s patient-specific prescription requirement as one of its conditions The clinical decision for each patient is still yours. Consider documenting:
- Your clinical rationale for each individual patient
- Patient consent, including that the product is compounded and not FDA-approved
- The specific peptide, form, and route, checked against Appendix B
Is a Compounded Peptide FDA-Approved?
No. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. None of these six peptides is an FDA-approved drug.
HHS states that its policy is meant to expand patient access while FDA reviews these substances. Enforcement discretion describes how HHS intends to use its enforcement resources. It is not an approval of any peptide or compounded product.
Where did the active ingredient come from?
An FDA-registered original manufacturer, with a Certificate of Analysis reviewed for each lot.
Can I see testing, not just a purity number?
Each batch is released with a Certificate of Conformance. Prescribers can request it.
What is a COC, and what is a COA?
A Certificate of Conformance (COC) is Empower’s batch-release document for a finished peptide; prescribers can request it. A Certificate of Analysis (COA) comes from the active ingredient manufacturer for each lot and, as reported, must show the manufacturer’s location under the HHS policy. Confirm details in the policy text.
503A vs 503B
- 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
- 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.
Frequently asked questions
Our team of experts has the answers you're looking for.
A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in all 50 states*, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.
*Licensing is subject to change.
Each injectable IV product will have the osmolarity listed on the label located on the vial.

Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (877) 562-8577.
We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.

Tirzepatide / Niacinamide Injection
Semaglutide / Methylcobalamin ODT
Semaglutide / Cyanocobalamin Injection
GHK-Cu Facial Serum
Sermorelin Acetate Injection
Sermorelin Acetate ODT
Gonadorelin Injection
Tirzepatide ODT
BPC-157 Acetate Troche
BPC-157 Acetate Injection